LIPIDIL SUPRA 100 MG TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Køb det nu

Hent Produktets egenskaber (SPC)
11-02-2014

Aktiv bestanddel:

FENOFIBRATE

Tilgængelig fra:

LABORATOIRES FOURNIER S.A.S.

ATC-kode:

C10AB05

INN (International Name):

FENOFIBRATE

Dosering:

100MG

Lægemiddelform:

TABLET

Sammensætning:

FENOFIBRATE 100MG

Indgivelsesvej:

ORAL

Enheder i pakken:

30

Recept type:

Prescription

Terapeutisk område:

FRIBIC ACID DERIVATIVES

Produkt oversigt:

Active ingredient group (AIG) number: 0118895002; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2014-01-29

Produktets egenskaber

                                1
PRODUCT MONOGRAPH
PR
LIPIDIL SUPRA
®
fenofibrate, microcoated formulation
film-coated tablets (160 mg)
LIPID METABOLISM REGULATOR
Laboratoires Fournier SAS
42 rue Rouget de Lisle
92150 Suresnes, France
Distributed by: Fournier Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
February 28, 2000
Date of Previous Revision:
November 13, 2013
Date of Revision: February 5, 2014
Submission Control No.:165706
® Lipidil Supra: Registered Trademark Fournier Industrie et Santé
Suresnes France; Licensed use by Fournier Pharma Inc., Saint-Laurent,
Quebec, H4S 1Z1
2
PRODUCT MONOGRAPH
PR
LIPIDIL SUPRA
®
fenofibrate, microcoated formulation
THERAPEUTIC CLASSIFICATION
Lipid Metabolism Regulator
ACTIONS AND CLINICAL PHARMACOLOGY
LIPIDIL SUPRA
®
(fenofibrate, microcoated formulation)
lowers elevated serum lipids by
decreasing the low density lipoprotein (LDL) fraction rich in
cholesterol and the very low
density lipoprotein (VLDL) fraction rich in triglycerides. In
addition, fenofibrate increases the
high density lipoprotein (HDL) cholesterol fraction.
Fenofibrate appears to have a greater depressant effect on the VLDL
than on the low density
lipoproteins (LDL). Therapeutic doses of fenofibrate produce
elevations of HDL cholesterol, a
reduction in the content of the low density lipoproteins cholesterol,
and a substantial reduction in
the triglyceride content of VLDL.
Fenofibrate is a fibric acid derivative whose lipid modifying effects
reported in humans are
mediated by the activation of a specific nuclear receptor called
peroxisome proliferator activated
receptor alpha (PPAR
α
), which produces:
•
a reduction in apo C-III, and therefore a reduction in the level of
dense atherogenic LDL
particles;
•
a stimulation of mitochondrial beta-oxidation, and therefore a
reduction in triglyceride
secretion;
•
a rise in lipoprotein lipase production, and therefore an acceleration
of triglyceride rich
lipoprotein breakdown;
•
a rise in apo A-I and apo A-II production.
Metabolism and Excret
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Produktets egenskaber Produktets egenskaber fransk 11-02-2014

Søg underretninger relateret til dette produkt